BIOMARIN PHARMACEUTICAL INC — Form 8-K/A
Filed July 13, 2026 · analyzed by the 8-K Agent
8-K/A
▲ Likely positive
significance 72/100
What the filing says
On December 19, 2025, BioMarin Pharmaceutical agreed to acquire Amicus Therapeutics for $14.50 per share in cash. The aggregate transaction value is approximately $5.3 billion, including $4.6 billion in direct equity consideration, $142.6 million for RSU/PSU settlements, $62.9 million for in-the-money option settlements, and $432.9 million to repay Amicus debt. The merger closed April 27, 2026, funded by $3.65 billion in new debt ($2.8B term facilities + $850M notes) and $1.84 billion in cash/liquidated investments.
Why this rating
Adds $634M annual revenue (17% growth), two marketed rare-disease drugs (Galafold, Pombiliti+Opfolda), significant intangibles ($4.75B), and pipeline asset. Material acquisition for $6.7B-market-cap target, though funding via substantial new debt ($3.65B) and cash burn create near-term leverage headwinds.
See more from July 13, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.